Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

NCT05649163 · clinicaltrials.gov ↗

UNKNOWN

Status

306

Enrollment

OTHER

Sponsor class

Conditions

HER2
Advanced Gastric Cancer
Advanced Gastroesophageal Junction Adenocarcinoma
Advanced Solid Tumor

Interventions

DRUG: Disitamab Vedotin

Sponsor

Shen Lin

Collaborators

[object Object]